Aethlon Medical, Inc. (AEMD)
| Market Cap | 3.76M +242.0% |
| Revenue (ttm) | n/a |
| Net Income | -8.07M |
| EPS | -17.80 |
| Shares Out | 711.14K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,469 |
| Open | 5.64 |
| Previous Close | 5.58 |
| Day's Range | 5.21 - 5.64 |
| 52-Week Range | 1.41 - 25.66 |
| Beta | 1.23 |
| Analysts | Hold |
| Price Target | 13.25 (+150.47%) |
| Earnings Date | Nov 12, 2026 |
About AEMD
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AEMD stock is "Hold." The 12-month stock price target is $13.25, which is an increase of 150.47% from the latest price.
News
Aethlon Medical Quarterly report: Q2 2027
Aethlon Medical has published its Q2 2027 quarterly earnings report on November 18, 2026.
Aethlon Medical Earnings release: Q2 2027
Aethlon Medical released its Q2 2027 earnings on November 18, 2026, summarizing the period's financial results.
Aethlon Medical reports Q2 EPS ($2.60) vs. ($18.70) last year
Cash and cash equivalents were approximately $6.5M as of September 30, 2026.
Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update
SAN DIEGO, Nov. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company, today announced financial results for fiscal secon...
Aethlon Medical Transcript: AGM 2026
Ten proposals were presented, including director elections, auditor ratification, share issuances, and amendments to equity and corporate structure. All proposals except the authorization of preferred stock were approved, with no questions from stockholders.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruger & Company, Inc. (NYSE – RGR), Atkore, Inc. (NYSE – ATKR), Centerspace (NYSE – CSR), Aethlon Medical, Inc. (Nasdaq – AEMD)
BALA CYNWYD, Pa., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
M&A News: Aethlon Medical Stock (AEMD) Rockets 400% After North Immunology Deal to Fight Eczema
Aethlon Medical ($AEMD) shares were nearly 400% higher in pre-market trading today after it announced it was merging with North Immunology to drive forward its innovative eczema treatment. Aethlon sai...
Aethlon Medical, North Immunology enter all-stock transaction
Aethlon Medical (AEMD) announced that it has entered into a definitive merger agreement for an all-stock transaction with North Immunology, Nighthawk Merger Sub Corp., a wholly owned subsidiary of Aet...
Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis
North Immunology's lead program, NOR-101, is a half-life extended anti-IL-13 x IL-18 bispecific antibody designed to inhibit both type 2 and non-type 2 inflammation, with the potential to deliver a be...
Aethlon Medical Proxy statement: Proxy filing
Aethlon Medical filed a proxy statement on September 4, 2026, providing details for shareholder voting and corporate governance matters.
Aethlon Medical Proxy statement: Proxy filing
Aethlon Medical filed a proxy statement on September 1, 2026, providing details for shareholder voting and corporate governance matters.
Aethlon Medical Proxy statement: Proxy filing
Aethlon Medical filed a proxy statement on August 21, 2026, providing details for shareholder voting and corporate governance matters.
Aethlon Medical Transcript: Emerging Growth Conference
Hemopurifier, a device targeting cancer and viral infections, is showing promising results in reducing harmful blood components in ongoing oncology trials, with strong safety data and extended impact from multiple treatments. Key milestones include trial completion, data analysis, and regulatory engagement.
Aethlon Medical Earnings Call Transcript: Q1 2027
Advanced to the final cohort of the oncology trial, with encouraging biomarker data and no serious adverse events so far. Cash position strengthened to $8.9 million post-quarter, supporting at least 12 months of operations. Disciplined cost control and expanded research into new disease areas continue.
Aethlon Medical Earnings release: Q1 2027
Aethlon Medical released its Q1 2027 earnings on August 13, 2026, summarizing the period's financial results.
Aethlon Medical Quarterly report: Q1 2027
Aethlon Medical has published its Q1 2027 quarterly earnings report on August 13, 2026.
Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program
Conference Call Today at 4:30 p.m. ET SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company, today announ...
Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026
SAN DIEGO, Aug. 5, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, tod...
Aethlon Medical trading halted, news pending
19:50 EDT Aethlon Medical (AEMD) trading halted, news pending
Aethlon Medical Transcript: Emerging Growth Conference
Hemopurifier, a blood filtration device, is showing promising early results in oncology trials by reducing harmful particles and supporting immune function. The company is well-financed, focused on completing its current trial, and aims to expand its platform to multiple disease areas.
Aethlon Medical announces results from Hemopurifier trial in Australia
Aethlon Medical (AEMD) announced that patients in the second cohort of its Australian oncology feasibility study demonstrated biological changes consistent with those previously observed in the first ...
Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®
Second cohort findings consistent with previously reported observations; independent statistical analysis planned following completion of all three patient cohorts SAN DIEGO, July 13, 2026 /PRNewswire...
Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
SAN DIEGO, July 6, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, tod...
Aethlon Medical Slides
Aethlon Medical has posted slides in relation to its latest quarterly earnings report, which was published on July 3, 2026.
Aethlon Medical Registration statement: Registration filing
Aethlon Medical filed a registration statement on July 1, 2026, providing details about a securities offering with the SEC.